CANDEL THERAPEUTICS, INC. (CADL)

Every figure this model derived for CADL, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2022-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 201,565,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 204,158,000 AssetsCurrent 2026-06-30
current liabilities 12,685,000 LiabilitiesCurrent 2026-06-30
equity 126,130,000 StockholdersEquity 2026-06-30
revenue 124,000 RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31
sbc 0 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CADL on one particular measure came for.

RatioValue
current ratio16.09
current ratio reported16.09
revenue growth0.0
revenue growth per share0.0
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about CADL's figures. Written by the derivation as it ran, not added afterwards.